Head to Head Contrast: Oncology Institute (NASDAQ:TOI) versus Todos Med (OTCMKTS:TOMDF)

Oncology Institute (NASDAQ:TOI) and Todos Med (OTCMKTS:TOMDF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Risk and Volatility

Oncology Institute has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Todos Med has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Profitability

This table compares Oncology Institute and Todos Med’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Todos Med	N/A	N/A	N/A

Institutional & Insider Ownership

36.9% of Oncology Institute shares are held by institutional investors. 4.4% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncology Institute and Todos Med”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73 million	1.10	-$60.61 million	($0.37)	-15.14
Todos Med	N/A	N/A	N/A	N/A	N/A

Todos Med has lower revenue, but higher earnings than Oncology Institute.

Analyst Ratings

This is a summary of current ratings and price targets for Oncology Institute and Todos Med, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1	0	4	0	2.60
Todos Med	0	0	0	0	0.00

Oncology Institute currently has a consensus target price of $7.75, indicating a potential upside of 38.39%. Given Oncology Institute’s stronger consensus rating and higher probable upside, research analysts plainly believe Oncology Institute is more favorable than Todos Med.

Summary

Oncology Institute beats Todos Med on 7 of the 9 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.